The present invention relates to new mGluR1 and mGluR5 receptor subtype preferring ligands of formula (I) and/or salts and/or hydrates and/or solvates and/or polymorphs thereof. The invention also relates to processes and intermediates for their preparation, to pharmaceutical compositions containing these compounds and to their use in treatment and/or prevention of conditions which require modulation of mGluR1 and mGluR5 receptors.
本发明涉及公式(I)的新型mGluR1和mGluR5受体亚型优先
配体和/或其盐和/或
水合物和/或溶剂化物和/或多晶体。本发明还涉及制备这些化合物的过程和
中间体,含有这些化合物的制药组合物以及它们在需要调节mGluR1和mGluR5受体的疾病的治疗和/或预防中的使用。